Novocure Ltd. (NVCR)

35.44
NASDAQ : Health Technology
Prev Close 35.44
Day Low/High 0.00 / 0.00
52 Wk Low/High 19.05 / 53.70
Avg Volume 885.70K
Exchange NASDAQ
Shares Outstanding 93.01M
Market Cap 3.24B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Novocure Announces More Than 70 Presentations On Tumor Treating Fields At 23rd Annual Meeting Of The Society For Neuro-Oncology

Novocure Announces More Than 70 Presentations On Tumor Treating Fields At 23rd Annual Meeting Of The Society For Neuro-Oncology

Novocure (NASDAQ: NVCR) today announced more than 70 presentations on Tumor Treating Fields, including five oral presentations, will be featured at the 23rd Annual Meeting of the Society for Neuro-Oncology (SNO) on Nov.

Novocure And Zai Lab To Host Investor Event

Novocure And Zai Lab To Host Investor Event

Novocure (NASDAQ: NVCR) announced today that it will host an investor event with Zai Lab on Nov.

Novocure Reports Third Quarter 2018 Financial Results And Provides Company Update

Novocure Reports Third Quarter 2018 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the three and nine months ended September 30, 2018.

Lululemon Athletica, Starbucks, Snap: 'Mad Money' Lightning Round

Lululemon Athletica, Starbucks, Snap: 'Mad Money' Lightning Round

Jim Cramer weighs in on Lululemon Athletica, Ollie's Bargain Outlet, Burlington Stores, Snap, Blackstone Group, NovoCure, Starbucks, Weight Watchers and more.

Novocure Founder Professor Yoram Palti And Director Louis J. Lavigne, Jr. Retire From Board Of Directors

Novocure Founder Professor Yoram Palti And Director Louis J. Lavigne, Jr. Retire From Board Of Directors

Novocure (NASDAQ: NVCR) announced today the retirement of Novocure founder Professor Yoram Palti, MD, PhD, and director Louis J.

Higher Delivered Dose Of Tumor Treating Fields To Tumor Bed Associated With Improved Overall Survival In Newly Diagnosed Glioblastoma

Higher Delivered Dose Of Tumor Treating Fields To Tumor Bed Associated With Improved Overall Survival In Newly Diagnosed Glioblastoma

Novocure (NASDAQ: NVCR) announced today results from a post-hoc analysis of Novocure's EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) that demonstrated that a higher dose of Tumor Treating Fields delivered to the tumor bed was...

Pancreatology Publishes Results Of The PANOVA Phase 2 Pilot Trial In Advanced Pancreatic Cancer Suggesting Improved Survival Of Patients Treated With Tumor Treating Fields

Pancreatology Publishes Results Of The PANOVA Phase 2 Pilot Trial In Advanced Pancreatic Cancer Suggesting Improved Survival Of Patients Treated With Tumor Treating Fields

Novocure (NASDAQ: NVCR) announced today that the results of its PANOVA phase 2 pilot trial have been published in Pancreatology .

Novocure Announces That The Medicare DME MACs Have Accepted The Local Coverage Determination Reconsideration Request For Optune®

Novocure Announces That The Medicare DME MACs Have Accepted The Local Coverage Determination Reconsideration Request For Optune®

Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma...

Novocure Announces 55 Presentations At European Association Of Neuro-Oncology Meeting 2018

Novocure Announces 55 Presentations At European Association Of Neuro-Oncology Meeting 2018

Novocure (NASDAQ: NVCR) announced today 55 presentations on Tumor Treating Fields at the European Association of Neuro-Oncology (EANO) Meeting 2018, Oct.

Novocure To Report Third Quarter 2018 Financial Results

Novocure To Report Third Quarter 2018 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2018 on Thursday, October 25, 2018, before the U.

Data From STELLAR Registration Trial Of Tumor Treating Fields In Mesothelioma To Be Presented At The IASLC 19th World Conference On Lung Cancer

Data From STELLAR Registration Trial Of Tumor Treating Fields In Mesothelioma To Be Presented At The IASLC 19th World Conference On Lung Cancer

Novocure (NASDAQ: NVCR) announced today that results from its STELLAR phase 2 registration trial in mesothelioma will be highlighted in an oral presentation at the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the...

Novocure And Zai Lab Announce Strategic Collaboration With A License Agreement For Tumor Treating Fields In Greater China

Novocure And Zai Lab Announce Strategic Collaboration With A License Agreement For Tumor Treating Fields In Greater China

Novocure (NASDAQ:NVCR), a global oncology company developing a proprietary platform technology called Tumor Treating Fields, and Zai Lab (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, announced today an exclusive license agreement...

Tumor Treating Fields Plus Standard Of Care Chemotherapy Significantly Extends Median Overall Survival By 6.1 Months In STELLAR Phase 2 Registration Trial In Mesothelioma Compared To Historical Control

Tumor Treating Fields Plus Standard Of Care Chemotherapy Significantly Extends Median Overall Survival By 6.1 Months In STELLAR Phase 2 Registration Trial In Mesothelioma Compared To Historical Control

Novocure (NASDAQ: NVCR) announced final results from its STELLAR phase 2 registration trial in mesothelioma, demonstrating a significant extension in median overall survival among patients treated with Tumor Treating Fields plus standard of care...

Novocure And US Oncology Research Announce Collaboration On PANOVA-3 Trial For Patients With Advanced Pancreatic Cancer

Novocure And US Oncology Research Announce Collaboration On PANOVA-3 Trial For Patients With Advanced Pancreatic Cancer

Novocure (NASDAQ: NVCR) and US Oncology Research are collaborating on PANOVA-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic...

Novocure To Present At Two Upcoming Investor Conferences

Novocure To Present At Two Upcoming Investor Conferences

Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences.

Novocure Announces Addition To Its Board Of Directors

Novocure Announces Addition To Its Board Of Directors

Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure's board in July 2018.

Gynecologic Oncology Publishes Results Of The INNOVATE Phase 2 Pilot Study Demonstrating Combination Of Tumor Treating Fields With Paclitaxel May Improve Survival Of Patients With Recurrent Ovarian Cancer

Gynecologic Oncology Publishes Results Of The INNOVATE Phase 2 Pilot Study Demonstrating Combination Of Tumor Treating Fields With Paclitaxel May Improve Survival Of Patients With Recurrent Ovarian Cancer

Novocure (NASDAQ: NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology.

Novocure Reports Second Quarter 2018 Financial Results And Provides Company Update

Novocure Reports Second Quarter 2018 Financial Results And Provides Company Update

Novocure (NASDAQ:NVCR) today reported financial results for the three and six months ended June 30, 2018.

Interesting NVCR Put And Call Options For March 2019

Interesting NVCR Put And Call Options For March 2019

Investors in NovoCure Ltd saw new options become available this week, for the March 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Novocure Announces 13 Presentations At American Society For Radiation Oncology 2018 Annual Meeting

Novocure Announces 13 Presentations At American Society For Radiation Oncology 2018 Annual Meeting

Novocure (NASDAQ: NVCR) announced today 13 presentations on Tumor Treating Fields at the American Society for Radiation Oncology (ASTRO) 2018 Annual Meeting, Oct.

Scientific Track Dedicated To Tumor Treating Fields At 40th International Conference Of The IEEE Engineering In Medicine And Biology Society

Scientific Track Dedicated To Tumor Treating Fields At 40th International Conference Of The IEEE Engineering In Medicine And Biology Society

Novocure (NASDAQ: NVCR) announced today that a scientific track has been dedicated to Tumor Treating Fields at the 40 th International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS), July 17 through July 21 in Honolulu, Hawaii.

Novocure Appoints Pritesh Shah As Chief Commercial Officer

Novocure Appoints Pritesh Shah As Chief Commercial Officer

Novocure (NASDAQ:NVCR) announced today that Pritesh Shah has been appointed as Novocure's Chief Commercial Officer, reporting to Novocure's Chief Executive Officer Asaf Danziger.

Novocure To Report Second Quarter 2018 Financial Results

Novocure To Report Second Quarter 2018 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2018 on Thursday, July 26, 2018, before the U.

NovoCure's Charts Look Bullish

NovoCure's Charts Look Bullish

NovoCure started a strong rally in 2017 and continues to move up.

Under Armour, Cognex, Novocure: 'Mad Money' Lightning Round

Under Armour, Cognex, Novocure: 'Mad Money' Lightning Round

Jim Cramer weighs in on Under Armour, Cognex, Novocure, FireEye, Weight Watchers, Bristol-Meyers Squibb and Chegg.

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

Jim Cramer explains why the fulcrum for the financial markets is growth -- not tariffs, or the Fed, or interest rates.

NVCR Crosses Above Average Analyst Target

NVCR Crosses Above Average Analyst Target

In recent trading, shares of NovoCure Ltd have crossed above the average analyst 12-month target price of $31.80, changing hands for $31.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Novocure To Present INNOVATE-3 Phase 3 Pivotal Trial Design In Recurrent Ovarian Cancer At The American Society Of Clinical Oncology Annual Meeting 2018

Novocure To Present INNOVATE-3 Phase 3 Pivotal Trial Design In Recurrent Ovarian Cancer At The American Society Of Clinical Oncology Annual Meeting 2018

Novocure (NASDAQ: NVCR) will present today for the first time the design of its phase 3 pivotal trial of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer at the American Society of Clinical...

TheStreet Quant Rating: D (Sell)